New Data Published in The Lancet Show GSK's Rotarix Offers
Protection Against the Most Common Circulating Rotavirus Types

PHILADELPHIA, November 23, 2007 /PRNewswire-FirstCall/ -- New
data from a large European clinical trial published today in The
Lancet show ROTARIX(R), GlaxoSmithKline's oral rotavirus candidate
vaccine to prevent rotavirus gastroenteritis, provides protection
against the five most commonly circulating rotavirus types around
the world and in the United States (U.S.). The GSK candidate
vaccine, if approved by the U.S. Food and Drug Administration
(FDA), would enable completion of the rotavirus vaccination series
by four months of age. Severe, dehydrating gastroenteritis occurs
most commonly among children aged three to 35 months. Of children
in the U.S. hospitalized with rotavirus, approximately one in five
are younger than six months old.

Results from this multi-center, randomized, double-blind,
placebo- controlled phase III clinical trial involving almost 4,000
European infants (candidate rotavirus vaccine n=2,572; placebo
n=1,302) demonstrated that two doses of ROTARIX provided highly
effective and sustained protection through two consecutive
rotavirus seasons (approximately two years of age). The data show
that, through two rotavirus seasons, the vaccine was highly
efficacious against rotavirus hospitalizations (96%), severe
rotavirus gastroenteritis (90%) and against rotavirus
gastroenteritis of any severity (79%). Specifically, significant
protection was demonstrated against severe rotavirus
gastroenteritis caused by types G1 (96%), G2 (86%), G3 (94%), G4
(95%), and G9 (85%), the most commonly circulating rotavirus types
around the world and in the United States.

"The candidate vaccine contains a live, weakened form of natural
human rotavirus derived from the most common human rotavirus strain
with the goal of offering protection against the most commonly
circulating and emerging rotavirus serotypes by mimicking the
protective effects of natural human rotavirus infection," said
David I. Bernstein, MD, MA, Director, Infectious Diseases; Gamble
Program at Cincinnati Children's Hospital Medical Center. "These
data are important because they confirm that immunization with two
doses of the rotavirus candidate vaccine could provide broad
protection against rotavirus gastroenteritis caused by emerging
types in addition to those that are already commonly
circulating."

In an additional analysis, protection against severe rotavirus
gastroenteritis in the period between dose one and dose two was
observed to be 90%. The protection offered by the two-dose schedule
of this rotavirus vaccine observed as early as after dose one is
particularly relevant as severe dehydrating rotavirus
gastroenteritis can occur in infants as young as three months of
age.

Since rotavirus is highly infectious, the spread of the disease
may be difficult to control. Vaccination against rotavirus is
recognized as the best measure to protect children against
rotavirus disease and has been shown to be highly effective in
preventing the disease.

The CDC Advisory Committee on Immunization Practices (ACIP), the
American Academy of Pediatrics (AAP), and the American Academy of
Family Physicians (AAFP) recommend that infants receive routine
vaccination with the rotavirus vaccine currently licensed by the
FDA at two, four, and six months of age in order to prevent
rotavirus gastroenteritis.

GSK's Biologics License Application (BLA) for the candidate
rotavirus vaccine is currently under review by the U.S. Food and
Drug Administration (FDA). It is proposed that the vaccine would be
given in two oral doses beginning at six weeks of age and completed
by 24 weeks of age, with a minimum four-week interval between the
doses. If approved, the vaccine could be integrated into the
current vaccine schedule at the two and four month immunization
visits.

About ROTARIX(R)

The GSK rotavirus candidate vaccine is a live-attenuated oral
rotavirus vaccine licensed in more than 100 countries around the
world. The vaccine is designed to prevent rotavirus gastroenteritis
by mimicking the protective effects of natural human rotavirus
infection. Studies have shown that natural rotavirus infection
provides significant protection from moderate to severe disease,
regardless of rotavirus strain. In clinical trials conducted in
support of US licensure, the most common solicited adverse
reactions were fussiness, runny nose, fever, loss of appetite, and
vomiting. Adverse reactions among recipients of ROTARIX and placebo
occurred at similar rates.

About Rotavirus

Rotavirus infects virtually every child worldwide by age five
and is the leading cause of severe acute gastroenteritis in infants
and young children in the U.S. and worldwide. Severe diarrhea and
dehydration occur primarily from as young as three months of age.
In the U.S. each year, 2.7 million children younger than five years
of age suffer from rotavirus disease, resulting in 410,000 clinic
visits and up to 272,000 emergency room visits. In addition,
between 55,000 and 70,000 children are hospitalized and 20-60 die
each year. In the U.S., the rotavirus season begins in the
southwest during November- December and spreads to the northeast by
April-May.

GlaxoSmithKline: A Leader in Vaccines

GlaxoSmithKline, with U.S. operations in Philadelphia, PA, and
Research Triangle Park, NC, is one of the world's leading
research-based pharmaceutical and healthcare companies and is
committed to improving the quality of human life by enabling people
to do more, feel better and live longer.

GSK Biologicals (GSK Bio), one of the world's leading vaccine
manufacturers, is headquartered in Rixensart, Belgium, where the
majority of GlaxoSmithKline's activities in the field of vaccine
research, development and production are conducted.

GSK Bio employs more than 1,500 scientists, who are devoted to
discovering new vaccines and developing more cost-effective and
convenient combination products to prevent infections that cause
serious medical problems worldwide. In 2006, GSK Bio distributed
more than 1.1 billion doses of vaccines to 169 countries in both
the developed and the developing world - an average of 3 million
doses a day. Of those vaccine doses, approximately 136 million were
doses of combination pediatric vaccines which protect the world's
children from up to six diseases in one vaccine.

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities
Litigation Reform Act of 1995, the company cautions investors that
any forward-looking statements or projections made by the company,
including those made in this Announcement, are subject to risks and
uncertainties that may cause actual results to differ materially
from those projected. Factors that may affect the Group's
operations are described under 'Risk Factors' in the 'Business
Review' in the company's Annual Report on Form 20-F for 2006.